ELOVL5 and cancer: The analyses of RNA-seq data of LNCaP/AR and LNCaP/AR-shp53/shRB [18] revealed that ELOVL5 was upregulated in NE-like enzalutamide resistant LNCaP/AR-shp53/shRB cells compared to LNCaP/AR cells (Figure 1E), which was further confirmed by RT-qPCR (Figure 1F) and the expression pattern in different cancer tissues (Figure S1C).